Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Current Liabilities (2021 - 2025)

Prime Medicine's Total Current Liabilities history spans 5 years, with the latest figure at $37.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 1.35% year-over-year to $37.4 million; the TTM value through Dec 2025 reached $37.4 million, down 1.35%, while the annual FY2025 figure was $37.4 million, 1.35% down from the prior year.
  • Total Current Liabilities reached $37.4 million in Q4 2025 per PRME's latest filing, up from $35.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $58.0 million in Q4 2021 to a low of $20.7 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $34.5 million, with a median of $34.3 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: tumbled 53.93% in 2022, then surged 111.21% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $58.0 million in 2021, then crashed by 53.93% to $26.7 million in 2022, then soared by 111.21% to $56.4 million in 2023, then plummeted by 32.72% to $38.0 million in 2024, then fell by 1.35% to $37.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Total Current Liabilities are $37.4 million (Q4 2025), $35.0 million (Q3 2025), and $34.1 million (Q2 2025).